Literature DB >> 8838775

The assessment of individual and population bioequivalence.

V M Chinchilli1.   

Abstract

We develop a statistical methodology for the assessment of individual bioequivalence when a crossover design is invoked. The location parameters for our model consist of population-averaged parameters for formulation, population-averaged parameters for nuisance effects (sequence, period, carryover, etc.), and subject-specific parameters for formulation. We do not impose any distributional assumptions other than the existence of first- and second-order moments. We derive unbiased estimators for all of the parameters in the model and construct subject-specific bioequivalence scores which exclude the effects of the nuisance parameters. We assess individual bioequivalence by constructing distribution-free tolerance intervals based on the sample of bioequivalence scores.

Mesh:

Substances:

Year:  1996        PMID: 8838775     DOI: 10.1080/10543409608835118

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  5 in total

1.  Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. FDA Population/Individual Bioequivalence Working Group. Food and Drug Administration.

Authors:  W W Hauck; T Hyslop; M L Chen; R Patnaik; R L Williams
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

2.  Bioequivalence of methylphenidate immediate-release tablets using a replicated study design to characterize intrasubject variability.

Authors:  M C Meyer; A B Straughn; E J Jarvi; K S Patrick; F R Pelsor; R L Williams; R Patnaik; M L Chen; V P Shah
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

3.  Variability in the bioavailability of phenytoin capsules in males and females.

Authors:  M C Meyer; A B Straughn; R M Mhatre; V P Shah; M L Chen; R L Williams; L J Lesko
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

4.  Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.

Authors:  R N Patnaik; L J Lesko; M L Chen; R L Williams
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

5.  Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.

Authors:  Jagdev Sidhu; Sarah Job; Jonathan Bullman; Emma Francis; Richard Abbott; John Ascher; Jochen G W Theis
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.